Introduction
Cardiofaciocutaneous syndrome (CFS) is a rare genetic disorder that affects approximately 1 in 800,000 births.1 The condition is classified by a series of heart abnormalities, various skin conditions and a distinct skull and face shape.2 These characteristics can often be accompanied by abnormal cognitive function or neurological pathologies such as feeding difficulties and seizures. Because of these, the children affected may have disrupted growth and may need feeding interventions such as nasogastric feeding. As a result of varied and often complex abnormalities, children with CFS require a lot of attention and care from various specialities, with the most attention needed to treat their heart conditions.
Understanding the Heart Conditions in CFS
Pathophysiology of Heart Issues
The underlying cause of CFS has been linked to the mutation of a few genes, all involved in the RAS/MAPK signalling pathway.3 During the normal development of a fetus, as the cells multiply, they send signals to each other and start differentiating into various cell types, eventually giving rise to tissues and organ structures. The RAS/MAPK pathway is an essential signalling pathway that is used throughout the development of the fetus, and is a key player in functions such as cell division, growth and differentiation.4 The most common genes associated with CFS are the BREF and MEK genes, which both code for proteins involved in the RAS/MAPK pathway.3 As a result of its widespread involvement in cell and organ development, normal development of many organs, particularly the heart, is disrupted, giving rise to CFS-associated abnormalities.
Associated heart abnormalities include:2
- Defective valves in the heart chamber and vessels, such as stiffening (stenosis)
- Abnormal rhythm due to defective conduction of electrical impulses in the heart muscle
- Defects within the septum separating the left and right sides of the heart
- Thickening of the heart muscle wall (hypertrophy) reduces the heart’s ability to pump efficiently, which can increase the risk of heart failure
Diagnosis of Heart Conditions in CFS
Early Recognition of Symptoms
The majority of congenital heart conditions are detected during pregnancy using ultrasound scans.5 The sonographer can view all four chambers of the heart and can detect abnormal heart function. Early detection and determination of the severity of the abnormality is essential for immediate, planned intervention after birth or, in severe cases, intervention during pregnancy.
Potential signs and symptoms that may present after birth are often related to insufficient blood circulation due to defective heart function. These may include cyanosis, fatigue, shortness of breath and failure to thrive.6,7 If a clinician performs a clinical exam, they may find an irregular rhythm of the heart or heart murmurs on auscultation, which may indicate a valve abnormality or atrial septal defect.
Diagnostic Tools
- Echocardiography - an ultrasound scan of the heart used to visualise the heart’s structure and monitor its function, including blood flow and contraction8
- Electrocardiogram (ECG) - an electrical tracing of the heart that can diagnose arrhythmias associated with CFS3
- Magnetic resonance imaging (MRI) and computed tomography - both scans can be used to capture more detailed, three-dimensional images of the heart if echocardiography is not sufficient8
- Genetic testing - used to identify mutations associated with the RAS/MAPK pathway and confirm diagnosis of CFS2
Treatment Options for Cardiac Issues in CFS
Management of cardiac issues in CFS patients must be under specialist care. Each patient would need to be reviewed and their heart function carefully assessed to determine appropriate treatment.
Medical Management
There are many medications available to reduce the risk of cardiovascular events and manage symptoms in CFS patients. Some conditions that can be managed with medication are:
- Heart failure - beta-blockers, diuretics and angiotensin-converting enzyme inhibitors9
- Arrhythmias - beta-blockers and blood thinners (anticoagulants) to reduce the risk of blood clots10
Surgical Interventions
For structural defects such as valve and septal abnormalities, surgical intervention may be required.11 Depending on the severity, defective valves may be replaced to restore blood flow and reduce the risk of heart failure. In the cases of atrial septal defects, where a hole remains patent between the right and left atria, once identified, they are monitored as they tend to spontaneously repair. However, if the hole shows no sign of resolving or too much blood is flowing between the right and left sides of the heart, surgical intervention may be indicated to repair the hole.
Other surgical interventions may include implants such as pacemakers and defibrillators.12 These may be indicated in CFS patients with severe arrhythmias to correct their heart rhythm and reduce the risk of sudden cardiac arrest and blood clotting.
Challenges in Treating Heart Conditions in CFS
It is essential to note that the treatments mentioned above are not cures to CFS, but rather supportive management and care to improve the quality of life and prevent further complications. Due to the complexity and multi-organ involvement in CFS, there may be difficulties in approaching management and treatment.2 For instance, overuse of medication may increase the risk of medication side-effects and adverse events, along with the risk of drug interactions if a patient is on more than one type of medication. Surgical interventions also have their associated risks. Furthermore, CFS patients are more likely to be under the care of a multi-disciplinary team, working in conjunction across different departments to provide treatment. Overlapping diseases, such as neurological and skin disorders, may increase the complexity of the approach a clinician takes to treat the associated heart problems.
Summary
- CFS is a rare genetic disorder caused by abnormalities in the RAS/MAPK signalling pathway, resulting in disrupted fetal development
- The most common abnormalities are associated with the heart, and these could be valve disease, atrial septal defects and arrhythmias
- Early diagnosis and intervention are critical for managing these heart conditions to improve the quality of life and prevent further complications
- Treatment may include a mix of medication and surgical intervention, specific to the needs of the patient
References
- Scorrano G, David E, Calì E, Chimenz R, La Bella S, Di Ludovico A, et al. The cardiofaciocutaneous syndrome: from genetics to prognostic–therapeutic implications. Genes (Basel) [Internet]. 2023 Nov 22 [cited 2025 Aug 18];14(12):2111. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10742720/
- Rauen KA. Cardiofaciocutaneous syndrome. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993 [cited 2025 Aug 18]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1186/
- Pierpont MEM, Magoulas PL, Adi S, Kavamura MI, Neri G, Noonan J, et al. Cardio-facio-cutaneous syndrome: clinical features, diagnosis, and management guidelines. Pediatrics [Internet]. 2014 Oct [cited 2025 Aug 18];134(4):e1149–62. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4179092/
- Tidyman WE, Rauen KA. The rasopathies: developmental syndromes of ras/mapk pathway dysregulation. Curr Opin Genet Dev [Internet]. 2009 Jun [cited 2025 Aug 18];19(3):230–6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743116/
- Sun HY. Prenatal diagnosis of congenital heart defects: echocardiography. Transl Pediatr. 2021 Aug;10(8):2210–24.
- Sun R, Liu M, Lu L, Zheng Y, Zhang P. Congenital heart disease: causes, diagnosis, symptoms, and treatments. Cell Biochem Biophys. 2015 Jul;72(3):857–60.
- Menon G, Poskitt EM. Why does congenital heart disease cause failure to thrive? Arch Dis Child [Internet]. 1985 Dec [cited 2025 Aug 18];60(12):1134–9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1777687/
- Iannotta M, d’Aiello FA, Bruaene AVD, Caruso R, Conte G, Ferrero P, et al. Modern tools in congenital heart disease imaging and procedure planning: a European survey. Journal of Cardiovascular Medicine (Hagerstown, Md) [Internet]. 2023 Dec 8 [cited 2025 Aug 18];25(1):76. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10754484/
- Bozkurt B. Contemporary pharmacological treatment and management of heart failure. Nat Rev Cardiol. 2024 Aug;21(8):545–55.
- King GS, Goyal A, Grigorova Y, Patel P, Hashmi MF. Antiarrhythmic medications. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Aug 18]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK482322/
- Rao PS. Management of congenital heart disease: state of the art; part i—acyanotic heart defects. Children (Basel) [Internet]. 2019 Mar 8 [cited 2025 Aug 18];6(3):42. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463202/
- Silvetti MS, Colonna D, Gabbarini F, Porcedda G, Rimini A, D’Onofrio A, et al. New guidelines of pediatric cardiac implantable electronic devices: what is changing in clinical practice? J Cardiovasc Dev Dis [Internet]. 2024 Mar 27 [cited 2025 Aug 18];11(4):99. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11050217/

